EAS – European Atherosclerosis Society

EAS Newsletter August 22, 2023 – EAS

EAS FHSC

Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines - Konstantinos C Koskinas, Baris Gencer, David Nanchen, Mattia Branca, David Carballo, Roland Klingenberg, Manuel R Blum, Sebastian Carballo

Evolving Management of Low‐Density Lipoprotein Cholesterol: A

EAS task force gives practical guidance for combination lipid-modifying therapy – EAS

Lipoprotein(a) Consensus 2022 – EAS

Livingcreation Werbeagentur

Lipitor Slide Deck- Role of high intensity statin in high CV risk patients.pptx

EAS Newsletter August 22, 2023 – EAS

Online courses – EAS

Sculpting New Treatment Strategies for High-Risk Patients With Dyslipidemia